- Home
- KOD vs HTFL Comparison
KOD vs HTFL Comparison
Compare KOD & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KOD | HTFL |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.2B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | KOD | HTFL |
|---|---|---|
| Price | $38.89 | $25.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $35.43 | ★ $38.20 |
| AVG Volume (30 Days) | ★ 1.6M | 1.6M |
| Earning Date | 05-13-2026 | 05-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $27.66 |
| Revenue Next Year | N/A | $23.55 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.92 | $20.13 |
| 52 Week High | $45.60 | $41.22 |
Technical Indicators
Market Signals| Indicator | KOD | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 64.44 | 54.16 |
| Support Level | $21.82 | $25.56 |
| Resistance Level | $45.60 | $28.98 |
| Average True Range (ATR) | 3.61 | 1.96 |
| MACD | 1.72 | 0.14 |
| Stochastic Oscillator | 73.03 | 60.45 |
Price Performance
Historical ComparisonAbout KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
About HTFL Heartflow Inc.
HeartFlow Inc is a commercial-stage medical technology company that has pioneered the use of software and AI to deliver a non-invasive solution for diagnosing and managing coronary artery disease CAD. The company operates and manages its business as one reportable and operating segment, which is the business of non-invasive coronary artery disease detection solutions. Geographically, it operates in United States, United Kingdom, Japan, and Rest of Europe, of which it derives maximum revenue from United States.